Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Puts New Flu Drug In Phase III Trials For H5N1 Effectiveness

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo has begun final-stage trials on a flu drug that could be effective against the bird flu virus. Daiichi's CS-8958 is to undergo its Phase III trial in Japan, Hong Kong, South Korea and Taiwan over the next four months, with influenza A or B patients the participants. The drug is to be tested in comparison with Roche's Tamiflu. Daiichi expects to file an approval application in Japan later next year. Daiichi also has begun separate trials for use of the drug as a pediatric treatment. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts